Literature DB >> 17107431

Tertian malaria (Plasmodium vivax and Plasmodium ovale) in two travelers despite atovaquone-proguanil prophylaxis.

Beatriz C Jiménez1, Miriam Navarro, Helena Huerga, Eva López-Román, Alfonso Mendoza, Rogelio López-Vélez.   

Abstract

There is limited data regarding the efficacy of prophylaxis with atovaquone/proguanil (A/P) against non-falciparum malaria in travelers. Two cases, one Plasmodium vivax infection and another Plasmodium ovale infection, in travelers despite A/P prophylaxis are presented.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17107431     DOI： 10.1111/j.1708-8305.2006.00073.x

Source DB:  PubMed          Journal:  J Travel Med        ISSN： 1195-1982            Impact factor:   8.490


  8 in total

Review 1.  What is the evidence for the existence of Plasmodium ovale hypnozoites?

Authors:  Joachim Richter; Gabriele Franken; Heinz Mehlhorn; Alfons Labisch; Dieter Häussinger
Journal:  Parasitol Res       Date:  2010-10-05       Impact factor: 2.289

Review 2.  Clinical implications of a gradual dormancy concept in malaria.

Authors:  Joachim Richter; Gabriele Franken; Martha C Holtfreter; Susanne Walter; Alfons Labisch; Heinz Mehlhorn
Journal:  Parasitol Res       Date:  2016-04-15       Impact factor: 2.289

3.  Towards an in vitro model of Plasmodium hypnozoites suitable for drug discovery.

Authors:  Laurent Dembele; Audrey Gego; Anne-Marie Zeeman; Jean-François Franetich; Olivier Silvie; Armelle Rametti; Roger Le Grand; Nathalie Dereuddre-Bosquet; Robert Sauerwein; Geert-Jan van Gemert; Jean-Christophe Vaillant; Alan W Thomas; Georges Snounou; Clemens H M Kocken; Dominique Mazier
Journal:  PLoS One       Date:  2011-03-31       Impact factor: 3.240

4.  Suppressive chemoprophylaxis invites avoidable risk of serious illness caused by Plasmodium vivax malaria.

Authors:  J Kevin Baird
Journal:  Travel Med Infect Dis       Date:  2013-02-28       Impact factor: 6.211

5.  Mixed-species Plasmodium falciparum and Plasmodium ovale malaria in a paediatric returned traveller.

Authors:  Heather Senn; Nadia Alattas; Andrea K Boggild; Shaun K Morris
Journal:  Malar J       Date:  2014-03-05       Impact factor: 2.979

6.  KAI407, a potent non-8-aminoquinoline compound that kills Plasmodium cynomolgi early dormant liver stage parasites in vitro.

Authors:  Anne-Marie Zeeman; Sandra M van Amsterdam; Case W McNamara; Annemarie Voorberg-van der Wel; Els J Klooster; Alexander van den Berg; Edmond J Remarque; David M Plouffe; Geert-Jan van Gemert; Adrian Luty; Robert Sauerwein; Kerstin Gagaring; Rachel Borboa; Zhong Chen; Kelli Kuhen; Richard J Glynne; Arnab K Chatterjee; Advait Nagle; Jason Roland; Elizabeth A Winzeler; Didier Leroy; Brice Campo; Thierry T Diagana; Bryan K S Yeung; Alan W Thomas; Clemens H M Kocken
Journal:  Antimicrob Agents Chemother       Date:  2013-12-23       Impact factor: 5.191

7.  Management of Plasmodium vivax risk and illness in travelers.

Authors:  J Kevin Baird
Journal:  Trop Dis Travel Med Vaccines       Date:  2017-03-28

8.  Imported malaria in Spain (2009-2016): results from the +REDIVI Collaborative Network.

Authors:  Francesca F Norman; Ana López-Polín; Fernando Salvador; Begoña Treviño; Eva Calabuig; Diego Torrús; Antonio Soriano-Arandes; Jose-Manuel Ruíz-Giardín; Begoña Monge-Maillo; Jose-Antonio Pérez-Molina; Ana Perez-Ayala; Magdalena García; Azucena Rodríguez; María Martínez-Serrano; Miren Zubero; Rogelio López-Vélez
Journal:  Malar J       Date:  2017-10-10       Impact factor: 2.979
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.